• Optimi (OPTI) is partnering with psilocybin patient advocate Thomas Hartle to produce a Canadian-grown and harvested natural therapeutic psilocybin product for patient use
  • Hartle’s charitable vision addresses equality and the lack of access to psilocybin-assisted therapy for vulnerable and underserved populations
  • The new product will be unveiled at a virtual press conference on Wednesday, August 10, 2022 at 1:00 pm ET
  • Optimi Health Corp. (OPTI) is down 2.70 per cent, trading at C$0.36 per share at 9:50 am ET

Optimi (OPTI) is partnering with psilocybin patient advocate Thomas Hartle to produce a Canadian-grown and harvested natural therapeutic psilocybin product for patient use.

Hartle’s charitable vision addresses equality and the lack of access to psilocybin-assisted therapy for vulnerable and underserved populations. Optimi has called this a critical component of the new partnership agreement.

Optimi Health CEO Bill Ciprick said that a problem needs to be solved – vulnerable and underserved adults are often excluded from the benefits of psilocybin therapy based on social, economic, gender, and racial factors beyond their control.

“Pain doesn’t discriminate, so hopefully our announcement with Thomas is a step in the right direction in addressing this urgent need.”

Thomas Hartle added that it wasn’t until he started receiving his psilocybin-assisted therapy treatments two years ago, he wasn’t sure if he could handle the daily stress of knowing that he was dying.

“Having a therapeutic psilocybin product made in my honour, which I had never considered as a possibility, gives me pause to reflect on how many have lost their battles before ever experiencing the amazing benefits of psilocybin therapy. I am excited to be partnering with Optimi to provide that opportunity to the people who need it most, with the hope that they will receive the same life restoring gift that I have experienced.”

The company intends to donate the proceeds from product sales directly to his charity to facilitate patient access to psilocybin-assisted therapy.

The new product will be unveiled at a virtual press conference on Wednesday, August 10, 2022 at 1:00 pm ET where Optimi executives and Mr. Hartle will discuss details of the partnership.

Optimi Health focuses on producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets.

Optimi Health Corp. (OPTI) is down 2.70 per cent, trading at C$0.36 per share at 9:50 am ET.


More From The Market Online

Sona Nanotech files patent application for photothermal light device

Sona Nanotech (CSE:SONA) submits a patent application to the U.S. Patent and Trademark Office for its proprietary photothermal light device.

You can strike gold and silver investment opportunities at Costco

Costco (NDAQ:COST), known for its wide array of products, also offers a distinct opportunity for investors: gold and silver.

FendX and McMaster University partner on spray nanotechnology

FendX Technologies (CSE:FNDX) reveals a partnership with McMaster University to advance the development of a spray nanotechnology.

Flow Beverage unveils sustainable packaging

Flow Beverage (TSX:FLOW) reveals new sustainable packaging to debut in the summer across North America in addition to a new brand platform.